T-cell subsets in scleroderma patients
暂无分享,去创建一个
Marie-Elise Truchetet | C. Chizzolini | M. Truchetet | Nicolò Costantino Brembilla | Elisa Montanari | Carlo Chizzolini | N. Brembilla | E. Montanari
[1] S. Gay,et al. The controversial role of tumor necrosis factor alpha in fibrotic diseases. , 2008, Arthritis and rheumatism.
[2] C. De Simone,et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea , 2010, The British journal of dermatology.
[3] J. Dayer,et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. , 2003, Arthritis and rheumatism.
[4] T. Medsger,et al. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. , 2003, Arthritis and rheumatism.
[5] T. Medsger,et al. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. , 2009, Arthritis and rheumatism.
[6] A. Freemont,et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.
[7] R. Corrocher,et al. Antibodies against Human Cytomegalovirus in the Pathogenesis of Systemic Sclerosis: A Gene Array Approach , 2005, PLoS medicine.
[8] A. del Rosso,et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations , 2004, Annals of the rheumatic diseases.
[9] Lisa M. Ebert,et al. A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells , 2004, The Journal of experimental medicine.
[10] H. Spits,et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.
[11] A. Fietta,et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. , 2009, Clinical and experimental rheumatology.
[12] I. Fajardy,et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. , 2009, Arthritis and rheumatism.
[13] A. Wells,et al. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial? , 2007, American journal of respiratory and critical care medicine.
[14] D. Elewaut,et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study , 2008, Annals of the rheumatic diseases.
[15] T. Krieg,et al. Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.
[16] K. Sullivan,et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. , 2006, Arthritis and rheumatism.
[17] T. Ohtsuka. Effect of γδ T cell supernatant on human skin fibroblast proliferation and collagen production – Possible role of transforming growth factor‐β and basic fibroblast growth factor , 2008, International journal of dermatology.
[18] R. Wise,et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. , 1999, Arthritis and rheumatism.
[19] B. Granel,et al. Implication de l'interleukine 13 et de son récepteur dans la sclérodermie systémique , 2007 .
[20] S. Jimenez,et al. Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.
[21] J. Banchereau,et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.
[22] U. Müller-Ladner,et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database , 2008, Annals of the rheumatic diseases.
[23] C. Denton,et al. Disease-modifying treatment in systemic sclerosis: current status , 2009, Current opinion in rheumatology.
[24] P. Dieudé,et al. Genetic background of systemic sclerosis: autoimmune genes take centre stage. , 2010, Rheumatology.
[25] M. Di Franco,et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease , 1997, Clinical and experimental immunology.
[26] E. Hofny,et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis , 2005, Journal of Clinical Pathology.
[27] M. Piccinni,et al. Microchimerism and Systemic Sclerosis , 2001, International Archives of Allergy and Immunology.
[28] M. Kahaleh,et al. γδ Receptor Bearing T Cells in Scleroderma: Enhanced Interaction with Vascular Endothelial Cellsin Vitro , 1999 .
[29] Y. Hamaguchi. Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis , 2010, The Journal of dermatology.
[30] D. Abraham,et al. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma , 2007, Nature Clinical Practice Rheumatology.
[31] Zhanju Liu,et al. Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. , 2009, World journal of gastroenterology.
[32] S. Durham,et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. , 2009, The Journal of clinical investigation.
[33] Till Acker,et al. Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis , 2004, Circulation research.
[34] A. Wells,et al. Pulmonary complications: one of the most challenging complications of systemic sclerosis. , 2006, Rheumatology.
[35] J. Varga. Systemic sclerosis: an update. , 2008, Bulletin of the NYU hospital for joint diseases.
[36] U. Müller-Ladner,et al. Renal complications and scleroderma renal crisis. , 2006, Rheumatology.
[37] D. Alarcón-Segovia,et al. Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. , 1995, Clinical and experimental rheumatology.
[38] M. Fujimoto,et al. Increased serum interleukin 23 in patients with systemic sclerosis. , 2008, The Journal of rheumatology.
[39] G. Pizzolo,et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. , 1997, The American journal of pathology.
[40] T. Flotte,et al. Interferons and collagen production. , 1990, The Journal of investigative dermatology.
[41] G. Damonte,et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells , 2000, Nature Medicine.
[42] R. Clark. Skin-resident T cells: the ups and downs of on site immunity. , 2010, The Journal of investigative dermatology.
[43] Francesco Boin,et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. , 2008, Arthritis and rheumatism.
[44] M. Mayes,et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. , 2001, Arthritis and rheumatism.
[45] R. Lafyatis,et al. The Pronounced Th17 Profile in Systemic Sclerosis (SSc) Together with Intracellular Expression of TGFβ and IFNγ Distinguishes SSc Phenotypes , 2009, PloS one.
[46] P. Merkel,et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. , 2009, Arthritis and rheumatism.
[47] A. Santoni,et al. Soluble interleukin‐2 receptor, interleukin‐2 and interleukin‐4 in sera and supernatants from patients with progressive systemic sclerosis , 1990, Clinical and experimental immunology.
[48] U. Müller-Ladner,et al. Mechanisms of vascular damage in systemic sclerosis , 2009, Autoimmunity.
[49] Annette Lee,et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus , 2010, Nature Genetics.
[50] M. Matucci-Cerinic,et al. Circulating γ/δ T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization , 2001 .
[51] D. Fox,et al. The role of T helper type 17 cells in inflammatory arthritis , 2010, Clinical and experimental immunology.
[52] M. Aurrand-Lions,et al. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. , 2007, Arthritis and rheumatism.
[53] M. Gruschwitz,et al. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. , 1997, Arthritis and rheumatism.
[54] M. Fujimoto,et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. , 2009, Arthritis and rheumatism.
[55] D. Artis,et al. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A , 2010, The Journal of experimental medicine.
[56] F. Annunziato,et al. Heterogeneity of human effector CD4+ T cells , 2009, Arthritis research & therapy.
[57] J. Reveille,et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. , 1996, Arthritis and rheumatism.
[58] V. Pascual,et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. , 2010, Arthritis and rheumatism.
[59] T. Krieg,et al. Localization of collagen mRNA in normal and scleroderma skin by in‐situ hybridization , 1988, European journal of clinical investigation.
[60] N. Bellamy,et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, Arthritis and rheumatism.
[61] T. Whiteside,et al. Functional and phenotypic analysis of T lymphocytes cloned from the skin of patients with systemic sclerosis , 1990, Clinical and experimental immunology.
[62] A. Wald,et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation , 2007, The Journal of experimental medicine.
[63] O. Distler,et al. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies , 2009, Annals of the rheumatic diseases.
[64] M. Fujimoto,et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? , 2008, Journal of dermatological science.
[65] Leroy Ec,et al. Autoimmunity and Vascular Involvement in Systemic Sclerosis (SSc) , 1999 .
[66] M. Hasegawa,et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. , 2000, The Journal of rheumatology.
[67] J. Dayer,et al. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts , 2005, Arthritis research & therapy.
[68] M. Mayes,et al. Extended Report , 2022 .
[69] C. Clavel,et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. , 1996, Archives of dermatology.
[70] J. Reveille,et al. The genetics of scleroderma (systemic sclerosis) , 2010, Current opinion in rheumatology.
[71] U. Müller-Ladner,et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.
[72] J. Rosenbloom,et al. Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies , 2010, Annals of Internal Medicine.
[73] M. Matucci-Cerinic,et al. Circulating Vδ1 + T cells are activated and accumulate in the skin of systemic sclerosis patients , 1998 .
[74] F. Sampogna,et al. a4b1+ and a4b7+ CD4+ T cell numbers increase and CLA+ CD4+ T cell numbers decrease in systemic sclerosis , 2005 .
[75] C. Boileau,et al. Genetic basis for systemic sclerosis. , 2007, Joint, bone, spine : revue du rhumatisme.
[76] David Abraham,et al. Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.
[77] K. Stengaard-Pedersen,et al. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. , 1998, British journal of rheumatology.
[78] W. Paul,et al. Heterogeneity and plasticity of T helper cells , 2010, Cell Research.
[79] H. Oberg,et al. Innate immune functions of human gammadelta T cells. , 2008, Immunobiology.
[80] K. Esposito,et al. Peripheral Blood T Lymphocytes from Systemic Sclerosis Patients Show Both Th1 and Th2 Activation , 2001, Journal of Clinical Immunology.
[81] Increased Frequency and Compromised Function of T Regulatory Cells in Systemic Sclerosis (SSc) Is Related to a Diminished CD69 and TGFβ Expression , 2009, PloS one.
[82] S. Carding,et al. γδ T cells: functional plasticity and heterogeneity , 2002, Nature Reviews Immunology.
[83] I. Douglas,et al. Regulatory Role of γδ T Cells in the Recruitment of CD4+ and CD8+ T Cells to Lung and Subsequent Pulmonary Fibrosis1 , 2006, The Journal of Immunology.
[84] K. Takabayashi,et al. Increased interleukin-17 production in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.
[85] M. Fujimoto,et al. Increased Serum Soluble OX40 in Patients with Systemic Sclerosis , 2008, The Journal of Rheumatology.
[86] S. Shete,et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. , 2009, Arthritis and rheumatism.
[87] C. Clavel,et al. Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. , 1992, European journal of cell biology.
[88] Charlie Strange,et al. Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.
[89] Brenda W Gillespie,et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. , 2003, Arthritis and rheumatism.
[90] Michael J. Grusby,et al. Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor α 2 , 2003, The Journal of experimental medicine.
[91] B. White,et al. The role of chemokines in the pathogenesis of scleroderma , 2003, Current opinion in rheumatology.
[92] T. Wynn. Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.
[93] R. Wise,et al. Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients. , 1994, Journal of immunology.
[94] I. Fajardy,et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. , 2009, Arthritis and rheumatism.
[95] L. Cosmi,et al. Chemoattractant Receptors Expressed on Type 2 T Cells and Their Role in Disease , 2001, International Archives of Allergy and Immunology.
[96] S. Shete,et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. , 2010, Journal of autoimmunity.
[97] C. Verweij,et al. Transcription profiling of rheumatic diseases , 2009, Arthritis research & therapy.
[98] M. Mayes,et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians , 2009, Annals of the rheumatic diseases.
[99] D. Abraham,et al. Overview of pathogenesis of systemic sclerosis. , 2006, Rheumatology.
[100] C. Meisel,et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients , 2009, Arthritis research & therapy.
[101] É. Rich,et al. Predicting Mortality in Systemic Sclerosis: Analysis of a Cohort of 309 French Canadian Patients with Emphasis on Features at Diagnosis as Predictive Factors for Survival , 2002, Medicine.
[102] D. Jarrossay,et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.
[103] K. Bost,et al. Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts. , 1992, Clinical immunology and immunopathology.
[104] H. Katai,et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. , 1992, The Journal of clinical investigation.
[105] R. Scrivo,et al. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. , 2005, The Journal of rheumatology.
[106] R. Clark,et al. The Vast Majority of CLA+ T Cells Are Resident in Normal Skin1 , 2006, The Journal of Immunology.
[107] Koichiro Nakamura,et al. The role of lymphocytes in healthy and eczematous skin , 2001, Current opinion in allergy and clinical immunology.
[108] F. Maquart,et al. Antagonistic Effects of Interferon-γ and Interleukin-4 on Fibroblast Cultures. , 1997 .
[109] D. Farge,et al. In Vitro Evidence for a Direct Antifibrotic Role of the Immunosuppressive Drug Mycophenolate Mofetil , 2007, Journal of Pharmacology and Experimental Therapeutics.
[110] F. Torricelli,et al. Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. , 2002, Arthritis and rheumatism.
[111] J. Sibilia,et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. , 2008, Seminars in arthritis and rheumatism.
[112] T. Matsushita,et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. , 2006, The Journal of rheumatology.
[113] P. Emery,et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.
[114] P. Dieudé,et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. , 2008, Arthritis and rheumatism.
[115] L. Settas,et al. Early T cell activation in the skin from patients with systemic sclerosis , 2005, Annals of the rheumatic diseases.
[116] D. Littman,et al. Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.
[117] S. Shete,et al. Association of Interleukin 23 Receptor Polymorphisms with Anti-Topoisomerase-I Positivity and Pulmonary Hypertension in Systemic Sclerosis , 2009, The Journal of Rheumatology.
[118] I. Bank,et al. Vgamma9+ gammadelta T cells in systemic sclerosis patients are numerically and functionally preserved and induce fibroblast apoptosis. , 2010, Immunobiology.
[119] A. Grassegger,et al. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis , 2007, Wiener Medizinische Wochenschrift.
[120] J. Gaudart,et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. , 2006, The Journal of rheumatology.
[121] T. Wynn. IL-13 effector functions. , 2003, Annual review of immunology.